Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 4 Asymmetric dimethylarginine (ADMA) inhibits incorporation of endothelial progenitor cells (EPCs) in tube-like structures. Incorporation of EPCs (labeled with 1,1'-dioctadecyl-3,3,3',3-tetramethyl-indocarbocyanine perchlorate labeled acetylated low-density lipoprotein [dil-ac-LDL]; red) in forming endothelial tubes from human umbilical vein endothelial cells (HUVECs) (labeled with UEA1-FITC; green) after treatment with increasing concentrations of ADMA or ADMA + rosuvastatin (RSV) (each n = 5). Two investigators in blinded experiments examined eight randomly selected high-power fields per experiment.
